I agree that this site is using cookies. You can find further informations here.
X
Sofen, Howard L.
83  results:
Search for persons X
?
1

Deucravacitinib onset of action and maintenance of response..:

Korman, Neil J. ; Warren, Richard B. ; Bagel, Jerry...
Journal of Dermatological Treatment.  35 (2024)  1 - p. , 2024
Link: https://doi.org/10.1080/..
 
?
2

Sustained Improvement in UAS7 After 16-Week Treatment With ..:

Maurer, Marcus ; McLaren, Julie ; Chon, Yun...
Journal of Allergy and Clinical Immunology.  153 (2024)  2 - p. AB373 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Deucravacitinib in Plaque Psoriasis: 3-year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  2 - p. s366 , 2024
Link: https://doi.org/10.25251..
 
?
4

Efficacy of Deucravacitinib, an Oral, Selective, Allosteric..:

Blauvelt, Andrew ; Sofen, Howard ; Lambert, Jo...
SKIN The Journal of Cutaneous Medicine.  8 (2024)  4 - p. s405 , 2024
Link: https://doi.org/10.25251..
 
?
5

Deucravacitinib, a selective, allosteric tyrosine kinase 2 ..:

Blauvelt, Andrew ; Rich, Phoebe ; Sofen, Howard...
Journal of the American Academy of Dermatology.  90 (2024)  4 - p. 775-782 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Lebrikizumab Improves Quality of Life and Patient-Reported ..:

Lio, Peter A. ; Armstrong, April ; Gutermuth, Jan...
Dermatology and Therapy.  14 (2024)  7 - p. 1929-1943 , 2024
Link: https://doi.org/10.1007/..
 
?
7

Efficacy and safety of tildrakizumab for the treatment of m..:

Gebauer, Kurt ; Spelman, Lynda ; Yamauchi, Paul S....
Journal of the American Academy of Dermatology.  91 (2024)  1 - p. 91-99 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine.  8 (2024)  4 - p. s406 , 2024
Link: https://doi.org/10.25251..
 
?
9

Deucravacitinib in plaque psoriasis: 2-year safety and effi..:

Lebwohl, Mark ; Warren, Richard B ; Sofen, Howard...
British Journal of Dermatology.  190 (2024)  5 - p. 668-679 , 2024
Link: https://doi.org/10.1093/..
 
?
10

Deucravacitinib versus placebo and apremilast in moderate t..:

Strober, Bruce ; Thaçi, Diamant ; Sofen, Howard...
Journal of the American Academy of Dermatology.  88 (2023)  1 - p. 40-51 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Oral spleen tyrosine kinase/Janus Kinase inhibitor gusaciti..:

Jimenez, Pablo A. ; Sofen, Howard L. ; Bissonnette, Robert...
Journal of the American Academy of Dermatology.  89 (2023)  2 - p. 235-242 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Pharmacokinetics, safety, and efficacy of cedirogant from p..:

Mohamed, Mohamed‐Eslam F. ; Qian, Yuli ; D'Cunha, Ronilda...
Clinical and Translational Science.  17 (2023)  1 - p. , 2023
Link: https://doi.org/10.1111/..
 
?
13

Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk ..:

Strober, Bruce ; Thaçi, Diamant ; Sofen, Howard...
Immunotherapy.  15 (2023)  11 - p. 787-797 , 2023
Link: https://doi.org/10.2217/..
 
?
14

Efficacy and safety of apremilast in patients with mild-to-..:

Gold, Linda Stein ; Papp, Kim ; Pariser, David...
Journal of the American Academy of Dermatology.  88 (2023)  2 - p. 430-433 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Deucravacitinib long-term efficacy with continuous treatmen..:

Lebwohl, Mark ; Warren, Richard B. ; Sofen, Howard...
SKIN The Journal of Cutaneous Medicine.  7 (2023)  2 - p. s118 , 2023
Link: https://doi.org/10.25251..
 
1-15